Cytiva has announced the completion of a project that doubles the liquid media production capacity at its Logan, Utah site. The expansion, detailed by group executive Pierre-Alain Ruffieux in a recent interview, aims to address supply chain demands as biopharma manufacturing reshoring accelerates in the United States and Europe.
The company is also making strides in manufacturing innovation. The FDA granted Cytiva's Elevecta transient cell line an Advanced Manufacturing Technology (AMT) designation, a recognition that could expedite its use in adeno-associated virus (AAV) production for gene therapies.
Cytiva's broader strategy includes an expanded collaboration with Chinese contract development and manufacturing organization (CDMO) Chime Biologics. This partnership is expected to strengthen its position in the Asian market, though specifics of the agreement were not provided.
Regarding artificial intelligence, Ruffieux discussed how Cytiva is integrating AI into its bioprocessing operations. However, no concrete product launches or timelines were disclosed in the interview, leaving specifics on AI applications forthcoming.
The company's efforts reflect a broader industry trend toward bolstering domestic manufacturing capacity. The Utah expansion positions Cytiva to better support drug developers with reliable media supply, a critical component for biologic and cell therapy production.